ID: ALA3683783

Max Phase: Preclinical

Molecular Formula: C14H13N5O

Molecular Weight: 267.29

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  NCc1ccnc(-n2[nH]cc(-c3cccnc3)c2=O)c1

Standard InChI:  InChI=1S/C14H13N5O/c15-7-10-3-5-17-13(6-10)19-14(20)12(9-18-19)11-2-1-4-16-8-11/h1-6,8-9,18H,7,15H2

Standard InChI Key:  ICCGIBTWBHPFQU-UHFFFAOYSA-N

Associated Targets(Human)

Von Hippel-Lindau disease tumor suppressor 136 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 267.29Molecular Weight (Monoisotopic): 267.1120AlogP: 1.08#Rotatable Bonds: 3
Polar Surface Area: 89.59Molecular Species: ZWITTERIONHBA: 5HBD: 2
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 5.87CX Basic pKa: 9.03CX LogP: -1.16CX LogD: -1.14
Aromatic Rings: 3Heavy Atoms: 20QED Weighted: 0.74Np Likeness Score: -1.04

References

1.  (2015)  4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases, 

Source

Source(1):